Clinical applications of recombinant CSF1-Fc produced in the eggs of transgenic hens in veterinary and human medicine

生物制品是一种药用蛋白质，在治疗一些以前难以治愈的疾病方面非常有效。它们在人类药物市场中的比例越来越大，但由于生产成本较高，在兽医环境中的广泛使用受到了阻碍。用转基因鸡取代昂贵的哺乳动物细胞培养系统，有很大的潜力降低这一成本。有了我们的系统，母鸡可以在整个产蛋期产生数量和活性一致的蛋白质，并使用标准技术进行纯化。在这里，我们打算通过大量的纯化和潜在的应用测试，在我们最近成功地在转基因蛋中生产活性猪CSF1-Fc的基础上继续发展。我们将扩大提纯规模，进行全面质量控制，在猪的人类疾病模型上进行测试，并将材料提供给其他专家进行评估。我们还将培育一个新的表达犬CSF1-Fc的转基因品系，为今后的兽医研究奠定基础。

Biologics are pharmaceutical proteins very effective at treating a number of previously intractable medical conditions. They are an increasing proportion of the human drugs market, but widespread use in veterinary settings has been prevented by high production cost. Replacing the expensive mammalian cell culture systems with transgenic chickens has significant potential to reduce this cost. With our system, hens can produce protein of consistent quantity and activity over their entire laying lives, and purification is performed using standard techniques. Here we propose to take forward our recent success producing active pig CSF1-Fc in transgenic hens' eggs by purifying large quantities and testing in potential applications. We will scale up purification, perform full quality control, test in pig models of human disease, and provide material to other experts for evaluation. We will also produce a new transgenic line expressing dog CSF1-Fc for future studies in veterinary medicine.